版本:
中国

J&J says stable patients likely to stay with Remicade

Oct 18 Johnson & Johnson, in a conference call with anlaysts:

* Says the 70 pct of patients stable on Remicade arthritis drug unlikely to switch to a biosimilar

* Says its Darzalex drug likely to become standard of care for multiple myeloma (Reporting by Ransdell Pierson)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐